Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $88 and keeps a Buy rating on the shares. 2026 is expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback